Synapse - GDMT, Medicine

Search Within

GDMT, Medicine

Results (1890)

The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: A 12-year experience at Memorial Sloan-Kettering Cancer Center

Journal Article

Abu-Rustum, N. R.; Alektiar, K.; Iasonos, A.; Lev, G.; Sonoda, Y.; Aghajanian, C.; Chi, D. S.; Barakat, R. R.
Gynecologic Oncology (2006)

Fulltext@MSK | Save

Ovarian cancer

Book Section

Rubin, S. C.; Sabbatini, P.; Alektiar, K.
In Pazdur, R.; Coia, L. R.; Hoskins, W. J.; Wagman, L. D. (Eds.) Cancer Management: A Multidisciplinary Approach. 9th ed (2005)

Fulltext@MSK | Save

Phase II trial of preoperative combined modality therapy for esophageal carcinoma: Induction cisplatin-irinotecan followed by concurrent cisplatinirinotecan and radiotherapy

Meeting Abstract

Tew, W. P.; Minsky, B.; Bains, M.; Rizk, N.; Rusch, V.; Kelsen, D. P.; Shah, M.; Kepler, S.; Gonen, M.; Ilson, D. H.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Paclitaxel and carboplatin (TP) for treatment of advanced or recurrent endometrial cancer: A retrospective study

Meeting Abstract

Sovak, M. A.; Chuai, S.; Anderson, S.; Barakat, R.; Dupont, J.; Hensley, M. L.; Sabbatini, P.; Spriggs, D. R.; Aghajanian, C.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors

Meeting Abstract

Monk, J. P.; Calero-Villalona, M.; Dupont, J.; Larkin, J.; Otterson, G.; Spriggs, D.; Hannah, A. L.; Cropp, G. F.; Johnson, R. G.; Hensley, M. L.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Paclitaxel, carboplatin plus gemcitabine (PCG) as first-line treatment for advanced epithelial ovarian cancer (EOC): Pathologic complete response (pCR) and impact on cognitive functioning

Meeting Abstract

Hensley, M. L.; Correa, D.; Thaler, H.; Wilton, A.; Venkatraman, E.; Sabbatini, P.; Chi, D.; Spriggs, D.; Aghajanian, C.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Clinical activity of single agent pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer (OC): Potential predictive relationship with tumor HER2 activation status

Meeting Abstract

Gordon, M. S.; Matel, D.; Aghajanian, C.; Matulonis, U.; Brewer, M.; Fleming, G.; Hainsworth, J.; Garcia, A. A.; Pegram, M.; Karlan, B.
EJC Supplements (2005)

Fulltext@MSK | Save

Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status

Meeting Abstract

Gordon, M. S.; Matei, D.; Aghajanian, C.; Matulonis, U. A.; Brewer, M. A.; Fleming, G. F.; Hainsworth, J. D.; Garcia, A. A.; Pegram, M.; Karlan, B. Y.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Prolonged dose-dense (DD) epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) in breast cancer (BCA) is feasible

Meeting Abstract

Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)

Meeting Abstract

Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save